

What is Viatriis doing to address antimicrobial resistance (AMR)?

As one of the world's largest suppliers of antimicrobials, including antibiotics and antiretrovirals, Viatriis is uniquely committed to addressing antimicrobial resistance (AMR). As a founding member of the AMR Industry Alliance (AMRIA), Viatriis has long believed in the power of cross-sectoral partnership to achieve greater results, together.

AMR is a complex problem and in many ways highlights broader issues impacting medicines and healthcare access more broadly. For example, many medicines are not taken appropriately, and therapeutic adherence is an issue for most people. This is a public health challenge because it represents an inefficient use of healthcare resources and won't result in intended health outcomes for individuals. The added complexity to this common challenge with antimicrobials is that lack of adherence and inappropriate use can result in the development of resistance by infectious pathogens to existing medicines. These resistant strains can quickly spread, multiplying the problem, potentially to pandemic scale.

Access to a wide array of high-quality antimicrobials and timely treatment are key in mitigating the rise of AMR. Viatriis has over 90 antimicrobials in our global portfolio, including many antibiotics that can be valuable in treating resistant bacteria. We recently launched a treatment for multi-drug resistant tuberculosis, only the third new anti-TB drug approved in the past half-century.

In 2022, Viatriis through the AMRIA contributed to work identifying root causes of and potential solutions for constraints in the off-patent antibiotic supply chain, participated in judging the second annual Stewardship Prize award for local programs demonstrating unique action to advance responsible use of antibiotics and collaborated in the launch of the first environmental manufacturing standard for antibiotics.

Fighting AMR via Responsible Manufacturing

As a founding member of the AMR Industry Alliance (AMRIA), we are committed to partnering across the industry to collectively advance initiatives addressing AMR. These efforts have led to progress in advancing science-based approaches to help manage the impact of antimicrobial manufacturing. We have adopted the AMRIA Common Antibiotic Manufacturing Standard for our own operations and external supply chain. Viatriis participated in the development of the Antibiotic Manufacturing Framework, which was then transitioned to a Standard in 2022 by the AMRIA. All applicable Viatriis manufacturing locations with antibiotic production have been assessed adhere to the AMRIA Antibiotic Manufacturing Standard, including meeting the PNEC (RQ<1) as calculated by mass balance. In our external supply chain, we are working on a phased approach to assess suppliers' management and performance on the AMRIA Antibiotic Manufacturing Standard. Suppliers that do not fully adhere to the AMRIA Antibiotic Manufacturing Standard develop and implement corrective actions. Viatriis monitors these

suppliers within established mitigation plans. For the work in the external supply chain, Viartis carried out 15 supplier risk assessments in 2022.

The Antibiotic Manufacturing Standard, facilitated by BSI Standards Limited (BSI), provides clear guidance to manufacturers in the global antibiotic supply chain to ensure that their antibiotics are made responsibly, helping to minimize the risk of AMR in the environment. The Standard marks the formalization of the Alliance's 2018 Common Antibiotic Manufacturing Framework, which described a risk-based approach to assessing and controlling antibiotic manufacturing waste streams.

The Antibiotic Manufacturing Standard, facilitated by BSI Standards Limited (BSI), provides clear guidance to manufacturers in the global antibiotic supply chain to ensure that their antibiotics are made responsibly, helping to minimize the risk of AMR in the environment. The Standard marks the formalization of the Alliance's 2018 Common Antibiotic Manufacturing Framework, which described a risk-based approach to assessing and controlling antibiotic manufacturing waste streams.